Skip to main navigation

Menu

Skip to content

Investors

Alnylam

E-mail Alerts

Download Center

Print

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter

Financial Information

FinancialMenu

Fundamentals
Financial Information
Quarterly Results
Key Ratios
Annual Reports

Here you will find a summary of Alnylam Pharmaceuticals, Inc.'s latest financial information.

Show all

Latest Earnings Release and 10-Q

Second Quarter Financial Results
Form 10-Q

Show all

Latest Annual Report and 10-K

2018 Annual Report 13.8 MB
Form 10-K

Show all

Latest Proxy Statement

Latest Proxy Statement

Share Related Items

Market Capitalization (Mil)	$8,973.35
Shares Outstanding (Mil)	111.21
Shares Outstanding, Average (FY) (Mil)	100.59
Float (Mil)	110.28

Copyright Thomson Reuters Corporation

FY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.

Search

Recent Press Releases

View all releases

Aug 14,2019

Summary Toggle Alnylam to Report New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias
Aug 13,2019

Summary Toggle Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
Aug 06,2019

Summary Toggle Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity

View all releases

: (Common):

Price:
Change (%):
Volume:
Data as of Copyright NASDAQ. Minimum 15 minutes delay

twitter
linkedin
youtube
rss

Copyright © 2019 Alnylam Pharmaceuticals, Inc. --- All Rights Reserved --- Glossary | Media Kit | Legal | Privacy Policy | Site Map